Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

The Journal of biological chemistry - 21 Nov 2008

Gozgit Joseph M, Bebernitz Geraldine, Patil Pankaj, Ye Minwei, Parmentier Julie, Wu Jiaquan, Su Nancy, Wang Tao, Ioannidis Stephanos, Davies Audrey, Huszar Dennis, Zinda Michael

Abstract excerpt

The Janus-associated kinase 2 (JAK2) V617F mutation is believed to play a critical role in the pathogenesis of polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. We have characterized a novel small molecule JAK2 inhibitor, AZ960, and used it as a tool to investigate the consequences of JAK2 V617F inhibition in the SET-2 cell line. AZ960 inhibits JAK2 kinase with a K(i) of 0.00045 microm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to bcl-Associated Death Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to Cell Survival

Share to Enzyme Inhibitors

Share to Janus Kinase 2

Share to Pyrazoles

Share to RNA, Small Interfering

Source

Identifiers

PMID: 18775810
DOI: 10.1074/jbc.M803813200

Genes

JAK2
BAD
SET
PIM1
PIM2
STAT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.PMID 18775810Read ↗

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.Semantic proximity Read ↗

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Semantic proximity Read ↗

JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.Semantic proximity Read ↗

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Semantic proximity Read ↗

Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1Semantic proximity Read ↗

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosisSemantic proximity Read ↗

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Semantic proximity Read ↗

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.Semantic proximity Read ↗

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.Semantic proximity Read ↗

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.Semantic proximity Read ↗

Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.Semantic proximity Read ↗

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.